Monk, B., Colombo, N., Tewari, K., Tekin, C., Keefe, S., Lorusso, D. (2024). Reply to P.-H. Luo et al. JOURNAL OF CLINICAL ONCOLOGY, 42(13), 1596-1598 [10.1200/JCO.24.00077].

Reply to P.-H. Luo et al

Colombo, N;
2024

Lettera in rivista
cancer chemotherapy; cancer immunotherapy; cancer patient; cancer recurrence; cancer survival; cervical metastasis; chemoradiotherapy; clinical evaluation; clinical practice guideline; clinical protocol; doublet chemotherapy; drug efficacy; drug safety; human; Letter; overall survival; patient risk; progression free survival; recurrent disease; statistically significant result; treatment response; upregulation; Wart virus
English
7-mar-2024
2024
42
13
1596
1598
none
Monk, B., Colombo, N., Tewari, K., Tekin, C., Keefe, S., Lorusso, D. (2024). Reply to P.-H. Luo et al. JOURNAL OF CLINICAL ONCOLOGY, 42(13), 1596-1598 [10.1200/JCO.24.00077].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/472662
Citazioni
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
Social impact